Why the study?
Alternative access sites have made transapical access less common in TAVR, prompting a detailed analysis of transapical access trends over 7 years.
How do the utilization trends and inpatient mortality of transapical access for TAVR compare to non-transapical access in patients with aortic stenosis?
How do the utilization trends and inpatient mortality of transapical access for TAVR compare to non-transapical access in patients with aortic stenosis?
Transapical access for TAVR has steadily declined in use from 2013 to 2017, accompanied by higher inpatient mortality, length of stay, and costs compared to non-transapical access.
Answers are grounded in this paper and cite their sources.
Declining TA-TAVR use may favor alternative accesses; leaves open comparative safety data in contemporary practice.
Introduction. The last decade has witnessed major evolution and shifts in the use of transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS). Included among the shifts has been the advent of alternative access sites for TAVR. Consequently, transapical access (TA) has become significantly less common. This study analyzes in detail the trend of TA access for TAVR over the course of 7 years. Methods. The national inpatient sample database was reviewed from 2011–2017 and patients with AS were identified by using validated ICD 9-CM and ICD 10-CM codes. Patients who underwent TAVR through TA access were classified as TA-TAVR, and any procedure other than TA access was classified as non-TA-TAVR. We compared the yearly trends of TA-TAVR to those of non-TA-TAVR as the primary outcome. Results. A total of 3,693,231 patients were identified with a diagnosis of AS. 129,821 patients underwent TAVR, of which 10,158 (7.8%) underwent TA-TAVR and 119,663 (92.2%) underwent non-TA-TAVR. After peaking in 2013 at 27.7%, the volume of TA-TAVR declined to 1.92% in 2017 ( p < 0.0001 ). Non-TA-TAVR started in 2013 at 72.2% and consistently increased to 98.1% in 2017. In-patient mortality decreased from a peak of 5.53% in 2014 to 3.18 in 2017 ( p = 0.6 ) in the TA-TAVR group and from a peak of 4.51% in 2013 to 1.24% in 2017 ( p = 0.0001 ) in the non-TA-TAVR group. Conclusion. This study highlights a steady decline in TA access for TAVR, higher inpatient mortality, increased length of stay, and higher costs compared to non-TA-TAVR.
No takes yet. Share an insight, caveat, or question.
Sohal et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: